ctDNA Guides Surgery for Recurrence
Executive Brief
- The News: ctDNA guides metastasis-directed therapy in select cases.
- Clinical Win: ctDNA prompts intervention more often than elevated CEA levels.
- Target Specialty: Oncologists managing stage II/III and IV CRC patients.
Key Data at a Glance
Condition: CRC (Colorectal Cancer)
Biomarker: ctDNA (circulating tumor DNA)
Alternative Biomarker: CEA (carcinoembryonic antigen)
Imaging Recommendation: Thin-slice, multiphase CT or contrast-enhanced MRI
Therapy Guidance: Metastasis-directed therapy (MDT)
Study Names: GALAXY and BESPOKE CRC
ctDNA Guides Surgery for Recurrence
A major challenge in clinical practice is determining how to respond to a positive circulating tumor DNA (ctDNA)ctDNA result following chemotherapy. When a recurrence is suspected, identifying a visible lesion becomes crucial, particularly if surgical resection is an option. This is where ctDNA can guide metastasis-directed therapy, offering the chance to surgically remove the source of recurrence in select cases. If chemotherapy has failed to clear residual disease, surgery guided by ctDNA detection may offer the best outcome—essentially a “home run” scenario for this biomarker.
Recent pooled data from the Galaxy GALAXY and bespoke BESPOKE CRC studies illustrate how ctDNA is being used to guide localized interventions. While Although use of metastasis-directed therapy was relatively uncommon in patients with stage II/III patientsdisease, it occurred more frequently in stage IV cases, particularly when ctDNA was positive. Notably, ctDNA results prompted intervention more often than elevated carcinoembryonic antigen (CEA) levels. This underscores a broader shift in clinical reliance—from the historically entrenched but inconsistent CEA marker toward the more sensitive and actionable ctDNA testing. CEA, though still in use, is increasingly viewed as unreliable, particularly in the context of modern precision oncology.
To act effectively on a ctDNA-positive result, high-quality imaging is essential. Basic or low-resolution scans may miss small, early metastases, undermining the potential benefit of ctDNA surveillance. Thin-slice, multiphase CT or contrast-enhanced MRI should be standard when ctDNA becomes positive, especially if the goal is curative resection. The sensitivity of the molecular test must be matched by the sensitivity of imaging, or opportunities for early salvage may be lost. Ultimately, combining advanced biomarkers with high-quality diagnostics and timely surgical decision-making can shift outcomes for patients—potentially offering curative interventions earlier than was possible using traditional surveillance methods alone.
Clinical Perspective — Dr. Meera Pillai, Oncology
Workflow: As I manage patients with suspected recurrence, I'm now more likely to use ctDNA to guide metastasis-directed therapy, particularly when surgery is an option. The Galaxy and BESPOKE CRC studies show that ctDNA can prompt intervention more often than elevated CEA levels, so I'm adjusting my approach to rely more on ctDNA testing. This means I'm ordering high-quality imaging, like thin-slice CT or contrast-enhanced MRI, when ctDNA is positive.
Economics: The article doesn't address cost directly, but I know that using ctDNA to guide therapy can potentially reduce costs in the long run by allowing for earlier, more targeted interventions. By combining advanced biomarkers with high-quality diagnostics, we may be able to avoid more expensive treatments down the line.
Patient Outcomes: For patients with positive ctDNA results, the potential benefit is significant - we may be able to offer curative resection, essentially a "home run" scenario. By using ctDNA to guide metastasis-directed therapy, we can potentially shift outcomes for patients and offer interventions earlier than traditional surveillance methods alone. This is especially important for patients with stage IV disease, where ctDNA can help identify opportunities for surgical removal of the source of recurrence.
Transparency & Corrections
HCP Connect is funded by Stravent LLC and maintains editorial independence from advertisers and pharmaceutical companies. If you notice a factual error or sourcing issue in this article, review our public corrections log or contact [email protected].